But HL can easily do some leverage financing, as is the case with many buyouts and having a patent coverage until 2040 would certainly help towards the financing.

If HL were to purchase all outstanding shares of RVX, dead money for three years, would need Chinese gov't funds.  Say good bye to RVX, all activities will be relocated to Shenzhen, less expensive, more control by gov't.  RVX will have a one room office in Canada. 

Hopefully in a buyout there will be many bidders.  We should all want RVX to stay in Canada.  Any BP is able to finance purchase, rates are at historic lows.

With a patent to 2040 there is greater value, buyout, I do see that as best way for all small shareholders, price, major guess, with potential 18M patients taking two doses daily, and some 23? other compounds on shelf waiting for funds, deep pockets will be rewarded.  Again, price before FDA approval, low between 4 to 10B, maybe lower, too may disappointments.  After FDA approval, all bets off!  Twenty years ago BP would purchase and take a chance, they all changed format, less gambling more proof.  With current round of financing, RVX can wait, can we?